Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Short term Debt (2017 - 2025)

Dr Reddys Laboratories (RDY) has 8 years of Short term Debt data on record, last reported at $15.7 million in Q1 2024.

  • For Q1 2024, Short term Debt fell 73.07% year-over-year to $15.7 million; the TTM value through Mar 2024 reached $15.7 million, down 73.07%, while the annual FY2025 figure was $445.0 million, 2718.47% up from the prior year.
  • Short term Debt reached $15.7 million in Q1 2024 per RDY's latest filing, down from $58.4 million in the prior quarter.
  • Across five years, Short term Debt topped out at $360.2 million in Q1 2022 and bottomed at $15.7 million in Q1 2024.
  • Average Short term Debt over 5 years is $162.1 million, with a median of $58.9 million recorded in 2020.
  • Peak YoY movement for Short term Debt: skyrocketed 438.85% in 2021, then crashed 83.77% in 2023.
  • A 5-year view of Short term Debt shows it stood at $58.9 million in 2020, then surged by 438.85% to $317.3 million in 2021, then grew by 13.51% to $360.2 million in 2022, then plummeted by 83.77% to $58.4 million in 2023, then tumbled by 73.07% to $15.7 million in 2024.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $15.7 million in Q1 2024, $58.4 million in Q1 2023, and $360.2 million in Q1 2022.